Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies.

Next Previous
X
Search
Trial Profile

A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies.

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Tipapkinogene sovacivec (Primary)
  • Indications Anal cancer; Carcinoma; Cervical cancer; Head and neck cancer; Liver metastases; Oropharyngeal cancer; Penile cancer; Squamous cell cancer; Vulvovaginal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Transgene

    • Most Recent Events

    • 14 Oct 2024 Primary endpoint (Phase II part 2: Progression Free Survival (PFS) by RECISIT 1.1) has not been met, according to a Transgene media release.
    • 14 Oct 2024 Top line results presented in a Transgene media release.
    • 02 Apr 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top